In partnership with Virginia Tech, Phase Inc ia addressing issues in the Microfluidic 3D Printig arena. A key factor in the development of next-generation therapeutics and diagnostic breakthroughs, Phase Inc argue that MF devices are the backbone of organ-on-a-chip and human-on-a-chip platforms - simulating a true biological environment within which solutions to critical medical issues can be addressed. Phase, Inc. has developed a 3D printing platform for microfluidics - a proprietary LE3D printing technology designed to enable biomimicry - employing the gold-standard biocompatible material not currently 3D-printable and a user interface that allows non-engineers readily to design and create microfluidics.
